OTCMKTS:UCBJY UCB (UCBJY) Stock Price, News & Analysis → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Free UCBJY Stock Alerts $64.54 +0.86 (+1.35%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$64.31▼$64.8650-Day Range$49.66▼$64.0552-Week Range$34.85▼$65.00Volume3,523 shsAverage Volume12,283 shsMarket CapitalizationN/AP/E Ratio84.53Dividend Yield0.55%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendFinancialsSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartDividendFinancialsSEC FilingsShort Interest Get UCB alerts: Email Address Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> About UCB Stock (OTCMKTS:UCBJY)UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.Read More UCBJY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UCBJY Stock News HeadlinesApril 18, 2024 | americanbankingnews.comUCB (OTCMKTS:UCBJY) Stock Price Passes Above 50-Day Moving Average of $57.90December 29, 2023 | seekingalpha.comDrugmakers reportedly planning to raise prices on 500+ drugs in January (update)April 19, 2024 | Behind the Markets (Ad)Tiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.December 29, 2023 | msn.comDrugmakers reportedly planning to raise prices on 500+ drugs in JanuaryDecember 28, 2023 | msn.comFDA’s new drug approvals for 2023 rise 51% from last yearDecember 1, 2023 | finance.yahoo.comUCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual MeetingNovember 14, 2023 | finance.yahoo.comUCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque PsoriasisOctober 18, 2023 | msn.comFDA approves UCB's Bimzelx for plaque psoriasisApril 19, 2024 | Behind the Markets (Ad)Tiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.October 4, 2023 | benzinga.comUCB presents late-breaking posters at Child Neurology Society MeetingSeptember 15, 2023 | msn.comEMA advisors recommend many new meds at latest meetingAugust 31, 2023 | markets.businessinsider.comSkin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst AssertsAugust 26, 2023 | msn.comCrohn's disease drugmakers set to benefit from expected rise in casesApril 13, 2023 | msn.comUCB (UCBJY) Declares $0.73 DividendApril 6, 2023 | wsj.comUnited Commercial Bank Ltd.March 20, 2023 | benzinga.comBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 WeeksDecember 23, 2022 | finance.yahoo.comUCB SA (UCBJY) Stock Historical Prices & Data - Yahoo FinanceDecember 9, 2022 | seekingalpha.comUCB drug meets main goals of 2 phase 3 trials for painful skin disorderNovember 8, 2022 | benzinga.comUCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022September 24, 2022 | benzinga.comUCB presents latest data from generalized myasthenia gravis portfolio at AANEM meetingSeptember 22, 2022 | finance.yahoo.comUCB SA (UCB.BR)September 17, 2022 | reuters.comUCB.BR - UCB SA | Stock Price & Latest News | ReutersSeptember 2, 2022 | benzinga.comUCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV CongressMay 11, 2022 | finance.yahoo.comUCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravisMay 4, 2022 | markets.businessinsider.comJAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)March 29, 2022 | markets.businessinsider.comFINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)March 28, 2022 | finance.yahoo.comUCB's Rare Childhood Epilepsy Drug Scores FDA ApprovalSee More Headlines Receive UCBJY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/19/2024Ex-Dividend for 5/15 Dividend4/26/2024Dividend Payable5/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:UCBJY CUSIPN/A CIK1290640 Webwww.ucb.com Phone(322) 559-9999FaxN/AEmployees8,450Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio83.41 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Jean-Christophe Tellier (Age 65)CEO & Executive Director Comp: $4.36MMs. Sandrine Dufour CFA (Age 58)Executive VP, CFO & Chief Corporate Development Dr. Kirsten Lund-Jurgensen Ph.D. (Age 64)Executive Vice President of Supply & Technology Solutions Dr. Dhavalkumar D. Patel M.D. (Age 63)Ph.D., Executive VP & Chief Scientific Officer Ms. Denelle J. Waynick Johnson J.D. (Age 57)Executive VP & General Counsel Mr. Jean-Luc Fleurial (Age 59)Executive VP & Chief Human Resources Officer Prof. Iris Low-Friedrich (Age 64)Executive VP & Chief Medical Officer Mr. Emmanuel Caeymaex (Age 55)Executive VP of Immunology Solutions & Head of US Ms. Caroline VancoillieChief Accounting Officer, Head of Group Finance & CFO of Patient Value FunctionsAntje WitteHead of Investor RelationsMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors UCBJY Stock Analysis - Frequently Asked Questions Should I buy or sell UCB stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" UCBJY shares. View UCBJY analyst ratings or view top-rated stocks. How have UCBJY shares performed in 2024? UCB's stock was trading at $43.60 on January 1st, 2024. Since then, UCBJY stock has increased by 48.0% and is now trading at $64.5350. View the best growth stocks for 2024 here. Are investors shorting UCB? UCB saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 200 shares, a decrease of 71.4% from the March 15th total of 700 shares. Based on an average daily volume of 13,300 shares, the short-interest ratio is currently 0.0 days. View UCB's Short Interest. How often does UCB pay dividends? What is the dividend yield for UCB? UCB declared a dividend on Friday, April 19th. Investors of record on Monday, April 29th will be paid a dividend of $0.4574 per share on Wednesday, May 15th. This represents a dividend yield of 0.71%. The ex-dividend date of this dividend is Friday, April 26th. Read our dividend analysis for UCBJY. Is UCB a good dividend stock? UCB (OTCMKTS:UCBJY) pays an annual dividend of $0.36 per share and currently has a dividend yield of 1.26%. The dividend payout ratio is 46.55%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for UCBJY. How do I buy shares of UCB? Shares of UCBJY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:UCBJY) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsSHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving TrendsUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.